AXT Buy Thesis Gains Ground, but Execution Risks Persist
Read source articleWhat happened
Seeking Alpha's Buy rating and $57 year-end 2027 target (50% upside) argues AXT's InP wafer process and upstream integration support pricing power, but the master report maintains a WAIT given export permit uncertainty, Coherent's internal capacity plans, and inventory overhang. The article applies a lower 18x earnings multiple than consensus 36x, acknowledging concentration, yet still implies a rebound that hinges on converting prepayments into shipments and sustaining AI-optics demand. Recent insider selling clusters in March and June, along with a CFO's large sale, raise questions about management's own conviction at these levels. Until quarterly results show substrate revenue above $22M and inventory below $95M, the stock's valuation is not supported by proven earnings power. The bull case requires Beijing 6-inch output ramping on schedule and Coherent not reducing external sourcing as it expands internal capacity.
Implication
The Seeking Alpha Buy aligns with the bull scenario only if export permits become routine and Coherent's prepayment converts to steady shipments. At $57, the stock would trade above the master report's base case of $48, implying meaningful execution already achieved. However, the master report's trim above $65 suggests limited upside to the bull case $70, while downside to bear $30 is larger. Insider selling in March and June after the stock's 2000% run signals caution from those with closest knowledge. Position sizing should reflect that the article's lower multiple still assumes significant earnings growth not yet visible in trailing results.
Thesis delta
The new article shifts sentiment from WAIT to BUY based on pricing power and demand, but does not alter the fundamental uncertainty around export permits and customer vertical integration. The target of $57 is between the base and bull scenarios, but the master report's conviction remains 4/10 due to lack of operational confirmation. The thesis delta is minor: the article adds a positive narrative but no new fundamental data, so the rating remains WAIT with a bias to upgrade on Q3 2026 results.
Confidence
Medium